表紙
市場調查報告書
商品編碼
975060

表觀遺傳學市場:按產品,應用,最終用戶:全球機會分析和行業預測(2020-2027)

Epigenetics Market by Product, Application, and End User : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日期: | 出版商: Allied Market Research | 英文 291 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2019年,全球表觀遺傳學市場為7.72億美元。到2020年至2027年,該市場預計將以13.6%的複合年增長率增長,到2027年將達到21.68億美元。

表觀遺傳學是由外部或生態學方面引發的細胞和生理學,它們可以不受基因型變化的影響打開和關閉基因,並影響細胞讀取基因的能力。一系列遺傳學,包括對性狀變化的研究。表觀遺傳學導致生物體表型的改變,而不是基因型的改變,而不改變基礎的DNA或RNA序列。表觀遺傳的變化是動態的,並且與環境刺激有關,是發展必不可少的。但是,這些更改可能是穩定的,可以從一代傳給另一一代。大多數生物的生物學和遺傳表達受表觀遺傳學影響,使其成為發育遺傳學和分子生物學的最重要領域之一。

表觀遺傳學市場包括癌症發病率上升,研究與開發活動增加,對研究與開發的快速投資,表觀遺傳非腫瘤疾病的廣泛應用以及學術,製藥和生物技術公司。由於它們之間夥伴關係的增加,預計在預測期內將顯著增長。然而,設備的高成本和缺乏訓練有素的專業人員阻礙了市場的增長。

此外,新興市場的未開發潛力為市場參與者提供了有利的機會。表觀遺傳學市場按產品,應用,最終用戶和地區分類。按產品劃分,分為□,試劑盒和測定法,儀器和試劑。□進一步分類為DNA連接□,DNA聚合□,其他DNA修飾□,乙□□,甲基轉移□,其他蛋白質修飾□,逆轉錄□,RNA連接□和其他RNA修飾□。該試劑盒進一步細分為ChIP測序試劑盒,亞硫酸氫鹽轉化試劑盒,全基因組擴增試劑盒,5-hmC和5-mC分析試劑盒,RNA測序試劑盒等。按儀器劃分,市場分為質量分析儀,下一代測序儀,qPCR,超聲儀等。試劑進一步分類為抗體,緩衝液,組蛋白,磁珠,引物等。

該報告探索了表觀遺傳學市場,提供了市場概況,按產品,應用,最終用戶,地區和進入市場的公司概況的趨勢。

目錄

第1章簡介

第2章執行摘要

第3章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資口袋
    • 2019年頂尖球員的排名
    • 主要成功策略
  • 波特的五力分析
  • 市場動態
    • 促進因素
      • 與表觀遺傳學有關的技術進步
      • 癌症發病率增加
      • 增加基因組作圖程序
      • 增加研發活動
    • 抑制因素
      • 關於基於表觀遺傳學的診斷方法的標準化問題
      • 缺乏熟練的專業人員
    • 市場機會
      • 新興市場的增長機會
    • 影響分析
  • 表觀遺傳學市場中COVID-19的影響分析

第4章表觀遺傳學市場:按產品

  • 概述
    • 市場規模和預測
  • 套件
    • 主要市場趨勢的增長因素和機遇
    • 市場規模和預測:按類型
      • ChIP序列試劑盒
      • 雙打戰鬥轉換套件
      • 全基因組擴增試劑盒
      • RNA測序試劑盒
      • 其他
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 試劑
    • 主要市場趨勢的增長因素和機遇
    • 市場規模和預測:按類型
      • 抗體
      • 磁珠
      • 希頓
      • 緩衝區
      • 入門
      • 其他
    • 市場規模和預測:按地區
    • 市場分析:按國家
    • 主要市場趨勢的增長因素和機遇
    • 市場規模和預測:按類型
      • DNA聚合□
      • 其他DNA修飾□
      • DNA連接□
      • 甲基轉移□
      • 乙□化□
      • 逆轉錄□
      • 其他蛋白質修飾□
      • RNA連接□
      • 其他RNA修飾□
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 儀器
    • 主要市場趨勢的增長因素和機遇
    • 市場規模和預測:按類型
      • 新一代音序器
      • qPCR
      • 質量分析儀
      • 聲波發生器
      • 其他
    • 市場規模和預測:按地區
    • 市場分析:按國家

第5章表觀遺傳學市場:按用途

  • 概述
    • 市場規模和預測
  • 腫瘤科
    • 市場規模和預測:按類型
      • 實體瘤
      • 液體腫瘤
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 非腫瘤學
    • 市場規模和預測:按類型
      • 代謝性疾病
      • 傳染病
      • 炎性疾病
      • 心血管疾病
      • 其他
    • 市場規模和預測:按地區
    • 市場分析:按國家

第6章表觀遺傳學市場:最終用戶

  • 概述
    • 市場規模和預測
  • 學術研究所
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 製藥和生物技術公司
    • 市場規模和預測:按地區
    • 市場分析:按國家
  • 合同研究組織
    • 市場規模和預測
    • 市場分析:按國家

第7章表觀遺傳學市場:按地區

  • 概述
    • 市場規模和預測
  • 北美
    • 關鍵市場趨勢,關鍵增長因素和機遇
    • 市場規模和預測:按國家
      • 美國
      • 加拿大
      • 墨西哥
    • 北美市場規模和預測:按產品
    • 北美表觀遺傳學市場:按應用
    • 北美表觀遺傳學市場:按最終用戶劃分
  • 歐洲
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測:按國家
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他
    • 歐洲市場規模和預測:按產品
    • 歐洲表觀遺傳市場:按應用
    • 歐洲表觀遺傳市場:按最終用戶劃分
  • 亞太地區
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他
    • 亞太市場規模和預測:按產品
    • 亞太表觀遺傳市場:按應用
    • 亞太表觀遺傳學市場:按最終用戶劃分
  • 拉美
    • 主要市場趨勢,增長因素和機遇
    • 市場規模和預測
      • 拉丁美洲
      • 中東和非洲
    • LAMEA市場規模和預測:按產品
    • LAMEA表觀遺傳學市場:按應用
    • LAMEA表觀遺傳學市場:按最終用戶劃分

第8章公司簡介

  • ABCAM PLC.
  • ACTIVE MOTIF, INC.
  • AGILENT TECHNOLOGIES, INC.
  • DIAGENODE DIAGNOSTICS
  • ILLUMINA, INC.
  • MERCK KGAA (MERCK MILLIPORE)
  • PERKINELMER, INC.
  • QIAGEN N.V.
  • THERMO FISHER SCIENTIFIC, INC.
  • ZYMO RESEARCH
目錄
Product Code: A00704

Title:
Epigenetics Market by Product (Kits, Reagents, Enzymes, and Instruments), Application (Oncology and Non-Oncology), and End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, and Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2020-2027.

The global epigenetics market was valued at $772 million in 2019, and is projected to reach $2,168 million by 2027, registering a CAGR of 13.6% from 2020 to 2027.

Epigenetics is a stream of genetics that involves study of cellular and physiological trait variations initiated by external or ecological aspects, which turn genes on and off and affect cellular ability to read genes without being affected by changes in genotype. Epigenetics results into changes in an organisms' phenotype rather than genotype, wherein the underlying DNA or RNA sequence remains unchanged. Epigenetic alterations are essential for development as they are dynamic and change with respect to environmental stimuli. However, these changes can be stable and could be passed from one generation to another. Biology and genetic expressions of most organisms are affected by epigenetics, which makes it one of the most crucial fields of developmental genetics and molecular biology.

The epigenetics market is expected to grow significantly during the forecast period, owing to rise in incidences of cancer, increase in R&D activities, surge in investments in R&D, growth in epigenetic applications for non-oncology diseases, and increase in partnership between academic, pharmaceutical, and biotechnology companies. However, high cost of instruments and lack of trained professionals impede the market growth.

Furthermore, untapped potential of emerging markets provide lucrative opportunities to the market players. The epigenetics market is segmented on the basis of product, application, end user, and region. By product, it is divided into enzymes, kits & assays, instruments, and reagents. Enzymes are further classified into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. Kits are further subdivided into ChIP sequencing kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and RNA sequencing kits, and others. On the basis of instrument, the market is categorized into mass spectrometers, next-generation sequencers, qPCRs, sonicators, and others. Reagents are further divided into antibodies, buffers, histones, magnetic beads, primers, and others.

On the basis of application, the market is classified into oncology and non-oncology. Oncology is further sub segmented into solid tumors and liquid tumors. Non-oncology applications include metabolic diseases, infectious diseases, inflammatory diseases, cardiovascular diseases, and other applications. By end user, it is classified into academic & government research institutes, pharmaceutical companies, biotechnology companies, and contract research organizations (CROs). By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Type

  • Kits
  • ChIP Sequencing Kits
  • Bisulfite Conversion Kits
  • Whole Genome Amplification Kits
  • 5-hmC & 5-mC Analysis Kits
  • RNA Sequencing Kits
  • Others
  • Reagents
  • Antibodies
  • Magnetic Beads
  • Histones
  • Buffers
  • Primers
  • Others
  • Enzymes
  • DNA Polymerases
  • Other DNA-Modifying Enzymes
  • DNA Ligases
  • Methyltransferases
  • Acetylases
  • Reverse Transcriptase
  • Other Protein-Modifying Enzymes
  • RNA Ligases
  • Others
  • Instruments
  • Next generation Sequencers
  • qPCRs
  • Mass Spectrometers
  • Sonicators
  • Others

By Application

  • Oncology
  • Solid Tumors
  • Liquid Tumors
  • Non-oncology
  • Metabolic diseases
  • Infectious diseases
  • Inflammatory diseases
  • Cardiovascular diseases
  • Other applications

By End User

  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Latin America
  • Middle East & Africa
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Abcam Plc.
  • Active Motif, Inc.
  • Agilent Technologies, Inc.
  • Diagenode
  • Illumina Inc.
  • Merck Millipore
  • PerkinElmer, Inc.
  • QIAGEN N.V.
  • Thermo Fisher Scientific Inc.
  • Zymo Research
  • LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
  • CellCentric Ltd.
  • Chroma Therapeutics Ltd.
  • Domainex
  • Eisai Co. Ltd
  • Novartis International AG,

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top player positioning, 2019
    • 3.2.3.Top winning strategies
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Technological advancements associated with epigenetics
      • 3.4.1.2.Increase in incidences of cancer
      • 3.4.1.3.Increase in genome mapping programs
      • 3.4.1.4.Increase in number of R&D activities
    • 3.4.2.Restraints
      • 3.4.2.1.Standardization concerns over epigenetics-based diagnostics
      • 3.4.2.2.Dearth of skilled professionals
    • 3.4.3.Opportunity
      • 3.4.3.1.Growth opportunities in emerging markets
    • 3.4.4.Impact analysis
  • 3.5.COVID-19 impact analysis on epigenetics market

CHAPTER 4:EPIGENETICS MARKET, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Kits
    • 4.2.1.Key market trends growth factors and opportunities
    • 4.2.2.Market size and forecast, by type
      • 4.2.2.1.ChIP sequencing kits
      • 4.2.2.1.1.Market size and forecast
      • 4.2.2.2.Bisulfite conversion kits
      • 4.2.2.2.1.Market size and forecast
      • 4.2.2.3.Whole genome amplification kits
      • 4.2.2.3.1.Market size and forecast
      • 4.2.2.4.5-hmC & 5-mC Analysis Kits
      • 4.2.2.4.1.Market size and forecast
      • 4.2.2.5.RNA Sequencing Kits
      • 4.2.2.5.1.Market size and forecast
      • 4.2.2.6.Others
      • 4.2.2.6.1.Market size and forecast
    • 4.2.3.Market size and forecast, by region
    • 4.2.4.Market analysis, by country
  • 4.3.Reagents
    • 4.3.1.Key market trends growth factors and opportunities
    • 4.3.2.Market size and forecast, by type
      • 4.3.2.1.Antibodies
      • 4.3.2.1.1.Market size and forecast
      • 4.3.2.2.Magnetic Beads
      • 4.3.2.2.1.Market size and forecast
      • 4.3.2.3.Histones
      • 4.3.2.3.1.Market size and forecast
      • 4.3.2.4.Buffers
      • 4.3.2.4.1.Market size and forecast
      • 4.3.2.5.Primers
      • 4.3.2.5.1.Market size and forecast
      • 4.3.2.6.Others
      • 4.3.2.6.1.Market size and forecast
    • 4.3.3.Market size and forecast, by region
    • 4.3.4.Market analysis, by country
  • 4.4.Enzymes
    • 4.4.1.Key market trends growth factors and opportunities
    • 4.4.2.Market size and forecast, by type
      • 4.4.2.1.DNA Polymerases
      • 4.4.2.1.1.Market size and forecast
      • 4.4.2.2.Other DNA-Modifying Enzymes
      • 4.4.2.2.1.Market size and forecast
      • 4.4.2.3.DNA Ligases
      • 4.4.2.3.1.Market size and forecast
      • 4.4.2.4.Methyltransferases
      • 4.4.2.4.1.Market size and forecast
      • 4.4.2.5.Acetylases
      • 4.4.2.5.1.Market size and forecast
      • 4.4.2.6.Reverse Transcriptase
      • 4.4.2.6.1.Market size and forecast
      • 4.4.2.7.Other protein-modifying enzymes
      • 4.4.2.7.1.Market size and forecast
      • 4.4.2.8.RNA Ligases
      • 4.4.2.8.1.Market size and forecast
      • 4.4.2.9.Other RNA-Modifying Enzymes
      • 4.4.2.9.1.Market size and forecast
    • 4.4.3.Market size and forecast, by region
    • 4.4.4.Market analysis, by country
  • 4.5.Instruments
    • 4.5.1.Key market trends growth factors and opportunities
    • 4.5.2.Market size and forecast, by type
      • 4.5.2.1.Next generation sequencers
      • 4.5.2.1.1.Market size and forecast
      • 4.5.2.2.qPCRs
      • 4.5.2.2.1.Market size and forecast
      • 4.5.2.3.Mass Spectrometers
      • 4.5.2.3.1.Market size and forecast
      • 4.5.2.4.Sonicators
      • 4.5.2.4.1.Market size and forecast
      • 4.5.2.5.Others
      • 4.5.2.5.1.Market size and forecast
    • 4.5.3.Market size and forecast, by region
    • 4.5.4.Market analysis, by country

CHAPTER 5:EPIGENETICS MARKET, BY APPLICATION

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Oncology
    • 5.2.1.Market size and forecast, by type
      • 5.2.1.1.Solid Tumors
      • 5.2.1.1.1.Market size and forecast
      • 5.2.1.2.Liquid Tumors
      • 5.2.1.2.1.Market size and forecast
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
  • 5.3.Non-oncology
    • 5.3.1.Market size and forecast, by type
      • 5.3.1.1.Metabolic diseases
      • 5.3.1.1.1.Market size and forecast
      • 5.3.1.2.Infectious diseases
      • 5.3.1.2.1.Market size and forecast
      • 5.3.1.3.Inflammatory diseases
      • 5.3.1.3.1.Market size and forecast
      • 5.3.1.4.Cardiovascular diseases
      • 5.3.1.4.1.Market size and forecast
      • 5.3.1.5.Others
      • 5.3.1.5.1.Market size and forecast
    • 5.3.2.Market size and forecast, by region
    • 5.3.3.Market analysis, by country

CHAPTER 6:EPIGENETICS MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Academic & research institutes
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Pharmaceutical & biotechnology companies
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Contract research organizations
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:EPIGENETICS MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, key growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
      • 7.2.2.1.U.S.
      • 7.2.2.1.1.U.S. epigenetics market, by product
      • 7.2.2.1.2.U.S. epigenetics market, by application
      • 7.2.2.1.3.U.S. epigenetics market, by end user
      • 7.2.2.2.Canada
      • 7.2.2.2.1.Canada epigenetics market, by product
      • 7.2.2.2.2.Canada epigenetics market, by application
      • 7.2.2.2.3.Canada epigenetics market, by end user
      • 7.2.2.3.Mexico
      • 7.2.2.3.1.Mexico epigenetics market, by product
      • 7.2.2.3.2.Mexico epigenetics market, by application
      • 7.2.2.3.3.Mexico epigenetics market, by end user
    • 7.2.3.North America market size and forecast, by Product
    • 7.2.4.North America epigenetics market, by application
    • 7.2.5.North America epigenetics market, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany epigenetics market, by product
      • 7.3.2.1.2.Germany epigenetics market, by application
      • 7.3.2.1.3.Germany epigenetics market, by end user
      • 7.3.2.2.France
      • 7.3.2.2.1.France epigenetics market, by product
      • 7.3.2.2.2.France epigenetics market, by application
      • 7.3.2.2.3.France epigenetics market, by end user
      • 7.3.2.3.UK
      • 7.3.2.3.1.UK epigenetics market, by product
      • 7.3.2.3.2.UK epigenetics market, by application
      • 7.3.2.3.3.UK epigenetics market, by end user
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy epigenetics market, by product
      • 7.3.2.4.2.Italy epigenetics market, by application
      • 7.3.2.4.3.Italy epigenetics market, by end user
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain epigenetics market, by product
      • 7.3.2.5.2.Spain epigenetics market, by application
      • 7.3.2.5.3.Spain epigenetics market, by end user
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe epigenetics market, by product
      • 7.3.2.6.2.Rest of Europe epigenetics market, by application
      • 7.3.2.6.3.Rest of Europe epigenetics market, by end user
    • 7.3.3.Europe market size and forecast, by Product
    • 7.3.4.Europe epigenetics market, by application
    • 7.3.5.Europe epigenetics market, by end user
  • 7.4.Asia-pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast
      • 7.4.2.1.Japan
      • 7.4.2.1.1.Japan epigenetics market, by product
      • 7.4.2.1.2.Japan epigenetics market, by application
      • 7.4.2.1.3.Japan epigenetics market, by end user
      • 7.4.2.2.China
      • 7.4.2.2.1.China epigenetics market, by product
      • 7.4.2.2.2.China epigenetics market, by application
      • 7.4.2.2.3.China epigenetics market, by end user
      • 7.4.2.3.Australia
      • 7.4.2.3.1.Australia epigenetics market, by product
      • 7.4.2.3.2.Australia epigenetics market, by application
      • 7.4.2.3.3.Australia epigenetics market, by end user
      • 7.4.2.4.India
      • 7.4.2.4.1.India epigenetics market, by product
      • 7.4.2.4.2.India epigenetics market, by application
      • 7.4.2.4.3.India epigenetics market, by end user
      • 7.4.2.5.South Korea
      • 7.4.2.5.1.South Korea epigenetics market, by product
      • 7.4.2.5.2.South Korea epigenetics market, by application
      • 7.4.2.5.3.South Korea epigenetics market, by end user
      • 7.4.2.6.Rest of Asia-Pacific
      • 7.4.2.6.1.Rest of Asia-Pacific epigenetics market, by product
      • 7.4.2.6.2.Rest of Asia-Pacific epigenetics market, by application
      • 7.4.2.6.3.Rest of Asia-Pacific epigenetics market, by end user
    • 7.4.3.Asia-Pacific market size and forecast, by Product
    • 7.4.4.Asia-Pacific epigenetics market, by application
    • 7.4.5.Asia-Pacific epigenetics market, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast
      • 7.5.2.1.Latin America
      • 7.5.2.1.1.Latin America epigenetics market, by product
      • 7.5.2.1.2.Latin America epigenetics market, by application
      • 7.5.2.1.3.Latin America epigenetics market, by end user
      • 7.5.2.2.Middle East & Africa
      • 7.5.2.2.1.Middle East & Africa epigenetics market, by product
      • 7.5.2.2.2.Middle East & Africa epigenetics market, by application
      • 7.5.2.2.3.Middle East & Africa epigenetics market, by end user
    • 7.5.3.LAMEA market size and forecast, by Product
    • 7.5.4.LAMEA epigenetics market, by application
    • 7.5.5.LAMEA epigenetics market, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.ABCAM PLC.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.ACTIVE MOTIF, INC.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Key strategic moves and developments
  • 8.3.AGILENT TECHNOLOGIES, INC.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
    • 8.3.6.Key strategic moves and developments
  • 8.4.DIAGENODE DIAGNOSTICS
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Key strategic moves and developments
  • 8.5.ILLUMINA, INC.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
    • 8.5.6.Key strategic moves and developments
  • 8.6.MERCK KGAA (MERCK MILLIPORE)
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
    • 8.6.5.Business performance
  • 8.7.PERKINELMER, INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.QIAGEN N.V.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segment
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.THERMO FISHER SCIENTIFIC, INC.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segment
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.ZYMO RESEARCH
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 02.EPIGENETICS KITS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 03.EPIGENETICS KITS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.EPIGENETICS REAGENTS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 05.EPIGENETICS REAGENTS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.EPIGENETICS ENZYMES MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 07.EPIGENETICS ENZYMES MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 08.EPIGENETICS INSTRUMENTS MARKET, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 09.EPIGENETICS INSTRUMENTS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 10.EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 11.EPIGENETICS MARKET FOR ONCOLOGY, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 12.EPIGENETICS MARKET FOR ONCOLOGY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.EPIGENETICS MARKET FOR NON-ONCOLOGY, BY TYPE, 2019-2027 ($MILLION)
  • TABLE 14.EPIGENETICS MARKET FOR NON-ONCOLOGY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.EPIGENETICS MARKET, BY END USER, 2019-2027 ($MILLION)
  • TABLE 16.EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 17.EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2027 ($MILLION)
  • TABLE 18.EPIGENETICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 19.EPIGENETICS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 20.NORTH AMERICA EPIGENETICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 21.U.S. EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 22.U.S. EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 23.U.S. EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 24.CANADA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 25.CANADA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 26.CANADA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 27.MEXICO EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 28.MEXICO EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 29.MEXICO EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 30.NORTH AMERICA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 31.NORTH AMERICA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 32.NORTH AMERICA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 33.EUROPE EPIGENETICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 34.GERMANY EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 35.GERMANY EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 36.GERMANY EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 37.FRANCE EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 38.FRANCE EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 39.FRANCE EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 40.UK EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 41.UK EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 42.UK EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 43.ITALY EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 44.ITALY EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 45.ITALY EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 46.SPAIN EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 47.SPAIN EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 48.SPAIN EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 49.REST OF EUROPE EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 50.REST OF EUROPE EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 51.REST OF EUROPE EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 52.EUROPE EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 53.EUROPE EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 54.EUROPE EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 55.ASIA-PACIFIC EPIGENETICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 56.JAPAN EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 57.JAPAN EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 58.JAPAN EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 59.CHINA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 60.CHINA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 61.CHINA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 62.AUSTRALIA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 63.AUSTRALIA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 64.AUSTRALIA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 65.INDIA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 66.INDIA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 67.INDIA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 68.SOUTH KOREA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 69.SOUTH KOREA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 70.SOUTH KOREA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 71.REST OF ASIA-PACIFIC EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 73.REST OF ASIA-PACIFIC EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 74.ASIA-PACIFIC EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 75.ASIA-PACIFIC EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 76.ASIA-PACIFIC EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 77.LAMEA EPIGENETICS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 78.LATIN AMERICA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 79.LATIN AMERICA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 80.LATIN AMERICA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 81.MIDDLE EAST & AFRICA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 82.MIDDLE EAST & AFRICA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 83.MIDDLE EAST & AFRICA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 84.LAMEA EPIGENETICS MARKET, BY PRODUCT, 2019-2027 ($MILLION)
  • TABLE 85.LAMEA EPIGENETICS MARKET, BY APPLICATION, 2019-2027 ($MILLION)
  • TABLE 86.LAMEA EPIGENETICS MARKET, BY END USER, 2019-2027
  • TABLE 87.ABCAM: COMPANY SNAPSHOT
  • TABLE 88.ALLERGAN: PRODUCT PORTFOLIO
  • TABLE 89.ACTIVE MOTIF: COMPANY SNAPSHOT
  • TABLE 90.ACTIVE MOTIF: OERATING SEGMENT
  • TABLE 91.ACTIVE MOTIF: PRODUCT PORTFOLIO
  • TABLE 92.AGILENT: COMPANY SNAPSHOT
  • TABLE 93.AGILENT: OERATING SEGMENT
  • TABLE 94.AGILENT: PRODUCT PORTFOLIO
  • TABLE 95.DIAGENODE: COMPANY SNAPSHOT
  • TABLE 96.DIAGENODE: OPERATING SEGMENTS
  • TABLE 97.DIAGENODE: PRODUCT PORTFOLIO
  • TABLE 98.ILLUMINA: COMPANY SNAPSHOT
  • TABLE 99.ILLUMINA: OPERATING SEGMENTS
  • TABLE 100.ILLUMINA: PRODUCT PORTFOLIO
  • TABLE 101.MERCK: COMPANY SNAPSHOT
  • TABLE 102.MERCK: OPERATING SEGMENTS
  • TABLE 103.MERCK: PRODUCT PORTFOLIO
  • TABLE 104.PERKINELMER: COMPANY SNAPSHOT
  • TABLE 105.PERKINELMER: OPERATING SEGMENT
  • TABLE 106.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 107.QIAGEN: COMPANY SNAPSHOT
  • TABLE 108.QIAGEN: PRODUCT SEGMENT
  • TABLE 109.PFIZER: PRODUCT PORTFOLIO
  • TABLE 110.THERMO FISHER SCIENTIFIC.: COMPANY SNAPSHOT
  • TABLE 111.THERMO FISHER SCIENTIFIC: PRODUCT SEGMENT
  • TABLE 112.SANOFI: PRODUCT PORTFOLIO
  • TABLE 113.ZYMO RESEARCH: COMPANY SNAPSHOT
  • TABLE 114.ZYMO RESEARCH: OPERATING SEGMENTS
  • TABLE 115.ZYMO RESEARCH: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.EPIGENETICS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP PLAYER POSITIONING, 2019
  • FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
  • FIGURE 05.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
  • FIGURE 06.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
  • FIGURE 07.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 08.LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 10.LOW THREAT OF SUBSTITUTION
  • FIGURE 11.HIGH COMPETITIVE RIVALRY
  • FIGURE 12.IMPACT ANALYSIS
  • FIGURE 13.CHIP SEQUENCING KITS MARKET, 2019-2027 ($MILLION)
  • FIGURE 14.BISULFITE CONVERSION KITS MARKET, 2019-2027 ($MILLION)
  • FIGURE 15.WHOLE GENOME AMPLIFICATION KITS MARKET, 2019-2027 ($MILLION)
  • FIGURE 16.5-HMC & 5-MC ANALYSIS KITS MARKET, 2019-2027 ($MILLION)
  • FIGURE 17.RNA SEQUENCING KITS MARKET, 2019-2027 ($MILLION)
  • FIGURE 18.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS EPIGENETICS KITS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 20.ANTIBODIES MARKET, 2019-2027 ($MILLION)
  • FIGURE 21.MAGNETIC BEADS MARKET, 2019-2027 ($MILLION)
  • FIGURE 22.HISTONES MARKET, 2019-2027 ($MILLION)
  • FIGURE 23.BUFFERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 24.PRIMERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 25.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 26.COMPARATIVE ANALYSIS EPIGENETICS REAGENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 27.DNA POLYMERASES MARKET, 2019-2027 ($MILLION)
  • FIGURE 28.OTHER DNA-MODIFYING ENZYMES MARKET, 2019-2027 ($MILLION)
  • FIGURE 29.DNA LIGASES MARKET, 2019-2027 ($MILLION)
  • FIGURE 30.METHYLTRANSFERASES MARKET, 2019-2027 ($MILLION)
  • FIGURE 31.ACETYLASES MARKET, 2019-2027 ($MILLION)
  • FIGURE 32.REVERSE TRANSCRIPTASE MARKET, 2019-2027 ($MILLION)
  • FIGURE 33.OTHER PROTEIN-MODIFYING ENZYMES MARKET, 2019-2027 ($MILLION)
  • FIGURE 34.RNA LIGASES MARKET, 2019-2027 ($MILLION)
  • FIGURE 35.OTHER RNA-MODIFYING ENZYMES MARKET, 2019-2027 ($MILLION)
  • FIGURE 36.COMPARATIVE ANALYSIS EPIGENETICS ENZYMES MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 37.NEXT GENERATION SEQUENCERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 38.QPCRS MARKET, 2019-2027 ($MILLION)
  • FIGURE 39.MASS SPECTROMETERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 40.SONICATORS MARKET, 2019-2027 ($MILLION)
  • FIGURE 41.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 42.COMPARATIVE ANALYSIS EPIGENETICS INSTRUMENTS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 43.EPIGENETICS MARKET FOR SOLID TUMORS, 2019 - 2027 ($MILLION)
  • FIGURE 44.EPIGENETICS MARKET FOR LIQUID TUMORS, 2019 - 2027 ($MILLION)
  • FIGURE 45.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR ONCOLOGY MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 46.EPIGENETICS MARKET FOR METABOLIC DISEASES, 2019 - 2027 ($MILLION)
  • FIGURE 47.EPIGENETICS MARKET FOR INFECTIOUS DISEASES, 2019 - 2027 ($MILLION)
  • FIGURE 48.EPIGENETICS MARKET FOR INFLAMMATORY DISEASES, 2019 - 2027 ($MILLION)
  • FIGURE 49.EPIGENETICS MARKET FOR CARDIOVASCULAR DISEASES, 2019 - 2027 ($MILLION)
  • FIGURE 50.EPIGENETICS MARKET FOR OTHERS, 2019 - 2027 ($MILLION)
  • FIGURE 51.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR NON-ONCOLOGY MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 52.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 53.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 54.COMPARATIVE ANALYSIS EPIGENETICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS MARKET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 55.U.S. EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 56.CANADA EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 57.MEXICO EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 58.GERMANY EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 59.FRANCE EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 60.UK EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 61.ITALY EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 62.SPAIN EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 63.REST OF EUROPE EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 64.JAPAN EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 65.CHINA EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 66.AUSTRALIA EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 67.INDIA EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 68.SOUTH KOREA EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 69.REST OF ASIA-PACIFIC EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 70.LATIN AMERICA EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 71.MIDDLE EAST & AFRICA EPIGENETICS MARKET, 2019-2027 ($MILLION)
  • FIGURE 72.ABCAM: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 73.ABCAM: REVENUE SHARE, BY REGION, 2019(%)
  • FIGURE 74.AGILENT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 75.AGILENT: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 76.AGILENT: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 77.ILLUMINA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 78.ILLUMINA: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 79.ILLUMINA: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 80.MERCK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 81.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 82.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 83.PERKINELMER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 84.PERKINELMER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 85.PERKINELMER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 86.QIAGEN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 87.QIAGEN: REVENUE SHARE, BY PRODUCT, 2019 (%)
  • FIGURE 88.QIAGEN: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 89.THERMO FISHER SCIENTIFIC, INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 90.THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 91.THERMO FISHER SCIENTIFIC. REVENUE SHARE, BY REGION, 2019 (%)